Introduction
The Halene Laboratory focuses on the study of myeloid malignancies and hematopoiesis. In particular we seek to understand the role of mutations in splicing factors, present in nearly 50% of patient with Myelodysplasia (MDS) and Acute Myeloid Leukemia (AML). In addition, we seek to establish a “co-clinical” model for MDS and AML with the goal to facilitate the translation of improved, less toxic, and more efficient treatments for MDS and AML into the clinic.
Twitter Feed
@Halene_lab Retweeted @chrisamillerIn our new preprint, we show that problems with the GRCh38 reference can cause in mutations in U2AF1 (a common cancer driver gene) to be missed. This is a big problem if you're looking at blood cancers or studying the spliceosome (1/6)
https://t.co/M7myTyRRAbA MONTH AGO
@Halene_labExcited to share our last research!
Altered #RNA binding by mutant U2AF1 results in increased formation of stress granules in myeloid malignancies. https://t.co/8m5j0rBboyA MONTH AGO
@Halene_lab Retweeted @YaleCancerJoin us at Noon today for a virtual .@YaleCancer Grand Rounds. Dr. Michael Hurwitz and Dr. Iris Isufi will be presenting "The Cell Therapy DART Solid Tumor Program" and "Cellular Therapies for Hematologic Malignancies at Yale." @SmilowCancer @YaleMed @YNHH https://t.co/s2xPSdSwj4 https://t.co/Y61SqTG2r93 MONTHS AGO
Principal Investigator
Stephanie Halene, MD, PhD
Associate Professor of Medicine (Hematology)
Contact Information
- Office
- Fax
- Appt